EU suspends Octagam
This article was originally published in Scrip
Executive Summary
Europe's Committee for Medicinal Products for Human Use (CHMP) has recommended the suspension and recall of Octagam (human normal immunoglobulin), produced by Octapharma, in all European Union states. Earlier this month, German and Swedish regulators suspended their marketing authorisations for Octagam following an unexpectedly high number of reports of thromboembolic events, including stroke, myocardial infarction and pulmonary embolism in patients receiving the medicine.